Bone erosions detected by ultrasound are prognostic for clinical arthritis development in patients with ACPA and musculoskeletal pain

Michael Ziegelasch (michael.ziegelasch@liu.se)
  Linköping University  https://orcid.org/0000-0002-1307-440X

Emma Eloff
  Department of Rheumatology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping

Hilde Bemer Hammer
  Department of Rheumatology, Diakonhjemmet Hospital, Oslo

Jan Cedergren
  Department of Rheumatology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping

Klara Martinsson
  Department of Rheumatology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping

Åsa Reckner
  Department of Rheumatology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping

Thomas Skogh
  Department of Rheumatology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping

Mattias Magnusson
  Department of Rheumatology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping

Alf Kastbom
  Department of Rheumatology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping

Research article

Keywords: Anti-citrullinated protein antibodies, rheumatoid arthritis, ultrasound, musculoskeletal pain

DOI: https://doi.org/10.21203/rs.3.rs-44899/v1
Abstract

Background

To assess the prognostic value of ultrasound for clinical arthritis development among anti-citrullinated peptide antibody (ACPA)-positive patients with musculoskeletal (MSK) pain.

Methods

We prospectively followed 82 ACPA-positive patients with MSK pain without clinical signs of arthritis at baseline. Ultrasound examination at baseline assessed synovial hypertrophy (SH), and inflammatory activity by power Doppler (PD) in 36 small joints and 6 tendons, and erosions in 18 joints. We applied Cox regression analyses to examine associations with clinical arthritis development during follow-up (median, 69 months; range, 24–90 months). We also compared the ultrasound findings among the patients to a control group of 100 blood donors without MSK pain.

Results

Clinical arthritis developed in 39/82 patients (48%) after a median of 6 months (range, 1–71 months). One or more ultrasound erosions occurred in 13/82 patients (16%), with none in control subjects (p < 0.001). Clinical arthritis development was more common among patients with baseline ultrasound erosions than those without (77% vs 42%, p = 0.032), and remained significant in a multivariable Cox regression analysis that included previously described prognostic factors (HR 3.9, 95% CI 1.6–9.4, p = 0.003). Ultrasound-detected tenosynovitis was more frequent among the patients and associated with clinical arthritis development in a univariable analysis (HR 2.5, 95% CI 1.1–5.7, p = 0.031), but did not remain statistically significant in multivariable analysis. Neither SH nor PD was associated with arthritis development.

Conclusions

Bone erosions detected by ultrasound are independent predictors of clinical arthritis development in an ACPA-positive at-risk population.

Trial registration

Regional Ethics Committee in Linköping, Sweden, Dnr M220-09. Registered 16 December 2009, https://etikprovningsmyndighetens.se/

Background

Autoimmune features, such as the presence of circulating rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA), typically precede the onset of clinically manifest rheumatoid arthritis (RA) (1, 2), as defined by the 1987 American College of Rheumatology (ACR87) or the 2010 Euro-American...
classification criteria (3, 4). Neither of these RA classification criteria is applicable to patients who are suffering from musculoskeletal (MSK) pain in the absence of clinical synovitis. However, given the benefits of modern early immunomodulatory therapies for RA (5) and the high diagnostic specificity of ACPA (6), patients within this category may benefit from anti-rheumatic drug therapy prior to fulfilling the classification criteria for RA. Nonetheless, considering the substantial risk of over-treatment with potent agents of immunomodulation in this clinical setting, there is a pressing need for predictors of disease development and progression. Ultrasound, which is an imaging modality that allows the detection of subclinical inflammation in musculoskeletal structures (7), could be valuable in identifying patients who could benefit from very early treatment.

Grey scale (GS) ultrasound visualizes thickening of the synovial membranes (synovial hypertrophy; SH) in joints and tendons, effusions, and structural bone changes, such as erosions (8). The addition of power Doppler (PD) to GS ultrasound findings allows for the detection of hyperemia, which is a sign of active inflammation (9). The use of MSK ultrasound to detect ongoing inflammation and, thereby, predict clinical arthritis development has shown potential in different at-risk populations (10–13), in particular regarding PD (14). However, there are divergent results regarding both the value of each ultrasound feature and whether or not they are predictive at the patient level (14, 15). Also, ultrasound findings of arthritis may occur among non-arthritic controls, although the frequency and magnitude need to be further detailed. Previous smaller studies have suggested that SH, particularly in the toes, may occur frequently in control populations without clinical arthritis (12, 14, 16).

In experienced hands, ultrasound appears to be more sensitive than conventional radiography for the detection of minimal structural changes located at bone surfaces (17, 18), although the prognostic value of ultrasound-detected erosions has been much less studied than SH and PD. One previous study reported a significant association between baseline ultrasound-detected erosions and subsequent development of arthritis, albeit without adjusting for possible confounders (14).

Ultrasound is increasingly used in clinical practice. In patients with RA-related autoantibodies and arthralgia, but no clinical arthritis, it is used for risk stratification and occasionally used for deciding on the initiation of disease-modifying anti-rheumatic drugs (DMARDs). However, a recent literature review concluded that the available evidence remains limited to moderate regarding the prognostic value of SH and PD, and insufficient concerning tenosynovitis and erosions (13).

Therefore, to fill these knowledge gaps, we compared the ultrasound findings of ACPA-positive patients with MSK pain but no clinical arthritis to the findings of healthy controls and investigated the prognostic value of ultrasound findings for subsequent clinical arthritis development.

**Methods**

**Patients and control subjects**
We set up a prospective observational study, designated ‘TIRx’ (Swedish acronym for “X-tra early rheumatology follow-up”), which enrolled 116 patients in the period of 2010–2013 at the University Hospital in Linköping, Sweden. The patients were referred from primary care centers within the Östergötland County in southeast Sweden to the rheumatology clinic, based on ACPA-positivity and any kind of MSK symptom. Screening, enrolment, and follow-up were performed by four experienced rheumatologists (AK, JC, TS, and ÅR). In this study we included patients with MSK pain of any sort and duration and a positive anti-cyclic citrullinated peptide (anti-CCP) antibody test in clinical routine practice. The exclusion criteria were: fulfilment of the ACR1987 criteria (3); oral or intraarticular corticosteroid therapy within 6 weeks prior to screening; previous diagnosis of inflammatory rheumatic disease; and age < 18 years. Twelve patients (10%) discontinued and 22 (19%) had clinical arthritis at baseline. Thus, 82 ACPA-positive at-risk patients were available for further analysis (Fig. 1). The baseline characteristics of the study subjects are shown in Table 1. Follow-up visits were scheduled at months 3, 12, 24, and 36, and thereafter every other year. Patients were instructed to contact the clinic without delay in case of increased symptoms between scheduled visits. At each visit, we obtained a 28-joint disease activity score (DAS28) (19) and conducted a clinical examination of symptomatic joint(s) not included in the 28-joint status. Pharmacotherapy and non-pharmacologic interventions were instituted as suggested by the physician and with the patient’s acceptance. Development of arthritis was defined by clinical examination conducted by an experienced rheumatologist. Follow-up was until September 1st 2017, resulting in a median follow-up time of 69 months [range, 24–90 months, interquartile range (IQR) 57–77] for those patients who did not develop arthritis.
As controls, we recruited 100 blood donors without MSK pain (Table 1.) from the Department of Transfusion Medicine at Linköping University Hospital. This control group was selected so as to have a similar mean age as the TIRx patient group, and the control subjects underwent ultrasound examination once according to the procedure described below.

### Ultrasound examinations

All ultrasound examinations were performed by an experienced rheumatologist (MZ) at baseline. The ProFocus system from BK Medical (BK Global Headquarters, Peabody, MA) with a linear scanner at 6–15 MHz was used. Synovial hypertrophy and bone erosions were assessed with identical GS settings for all participants (B-mode frequency, 12 MHz; B-mode gain, 25 dB), while inflammatory activity was assessed by power Doppler (frequency, 7.5 MHz; Doppler gain 44dB; pulse repetition frequency, 0.8 kHz; and the lowest possible wall filter to avoid artefacts). The protocol included dorsal assessments of the
following 36 joints: bilateral radiocarpal, intercarpal, distal radioulnar, metacarpophalangeal (MCP) joints 1–5, interphalangeal (IP) thumb joints, proximal interphalangeal (PIP) joints 2–5, and metatarsophalangeal (MTP) joints 1–5.

To grade synovitis, we used the semi-quantitative scoring system introduced by Szkudlarek et al. (20) in which gray-scale synovial SH and hyperemia (PD) were graded on a scale of 0–3. We used the commonly applied definition of ultrasound arthritis of SH ≥ 2 and/or PD grade ≥ 1 as the cutoff for a pathologic ultrasound finding (8, 16, 21–23). PD signals were assessed only in joints with SH ≥ 1. Sum scores from the 36 investigated joints were calculated for SH and PD, respectively, resulting in a maximum score of 108 for both SH and PD.

In addition, three of the most commonly involved tendons in RA were examined bilaterally (extensor carpi ulnaris (ECU), tibialis posterior tendon (TPT), and common flexor digitorum longus (CFDL) in the feet) (24). Tenosynovitis was scored by GS according to OMERACT (8), and PD signals were scored as: 0 = none; 1 = minor; 2 = moderate; and 3 = major presence (24).

Regarding erosions, easily assessable and typical sites (MCP 2 and 5, ulnar head, PIP 2–5, and MTP 1 and 5) were examined bilaterally, and erosions were reported as present (≥ 1) or not present. Erosion was defined as an interruption of the bone surface observed in two perpendicular planes with a diameter of ≥ 1 mm (8).

The ultrasound investigator did not participate in the clinical management of the patients, and the ultrasound results were blinded to both the patients and their respective physicians during the first 3 years of the study. Thereafter, they were available upon request. To determine the intra-reader reliability, baseline ultrasound images of 36 joints from 10 randomly chosen patients (in total 360 joints) were saved and re-assessed at least 2 weeks later, resulting in a kappa value of 0.948 for the presence of ultrasound synovitis (categorically as defined above), and 1.0 for the presence of erosions.

**Laboratory analyses**

Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were analyzed according to clinical routine practice at the Clinical Chemistry Laboratory, Linköping University Hospital. Agglutinating RF was analyzed by nephelometry at the accredited Clinical Immunology Laboratory, Linköping University Hospital (cutoff, 30 U/mL). In serum samples collected at baseline and stored at -80 °C, anti-CCP antibodies were analyzed using the 2nd generation enzyme immunoassay (Immunoscan CCPlus; EuroDiagnostica AB, Malmö, Sweden). The cutoff was set at 25 AU/mL according to the manufacturer.

**Statistical analyses**

Statistical analyses were performed using the IBM SPSS Statistics 23 software. Continuous data were summarized with mean values and standard deviation, and non-normally distributed data with median values and IQR. Differences between groups were tested using the Student’s t-test regarding continuous variables, and proportions were compared using the Chi-squared test. To assess the prognostic value of
ultrasound features for clinical arthritis development, we performed univariable Cox regression analysis. Significant findings were further tested in a multivariable analysis that included baseline variables of potential importance for arthritis development (age, sex, symptom duration, RF status, ACPA levels, smoking habits, ESR, and CRP levels). Positive predictive values (PPV) and negative predictive values (NPV) for the ultrasound findings were calculated for significant associations in the multivariable model. Statistical significance was adjudged for two-sided p-values < 0.05.

Results

Ultrasound findings in patients and controls

At the joint level, significantly more MCP and PIP joints had SH ≥ 2 among the patients, as compared to the controls (Table 2). In contrast, SH ≥ 2 was more prevalent in MTP 1–5 among controls than among patients (30.2% vs. 18.7%, p < 0.001). Among the controls, SH was more frequent in MTP 1–4 than in any other location and was significantly over-represented compared to the patients (Table 2). Therefore, we decided to present MTP 1–4 separately from MTP 5, and to exclude MTP 1–4 from the analyses of SH versus arthritis development in the patients.
Table 2
Comparison of ultrasound abnormalities at among anti-citrullinated protein antibody-positive at-risk patients versus controls.

| Joint(s) | Synovial hypertrophy ≥ 2 | Power Doppler ≥ 1 |
|----------|--------------------------|------------------|
|          | Patients (n = 82) | Controls (n = 100) | p-value | Patients (n = 82) | Controls (n = 100) | p-value |
| Wrist    | 8.9% (44/492) | 7.0% (42/600) | 0.259 | 7.9% (39/492) | 2% (12/600) | < 0.001 |
| MCP 1–5  | 3.5% (29/820) | 0.5% (5/1000) | < 0.001 | 0.7% (6/820) | 0% (0/1000) | 0.008 |
| PIP 2–5  | 5.0% (33/656) | 0.6% (5/800) | < 0.001 | 1.7% (11/656) | 0% (0/800) | < 0.001 |
| MTP 1–4  | 22.1% (145/656) | 37.4% (299/800) | < 0.001 | 2.1% (14/656) | 0.3% (2/800) | 0.001 |
| MTP 5    | 4.9% (8/164) | 1.5% (3/200) | 0.071 | 1.2% (2/164) | 0% (0/200) | 0.202 |
| Total    | 9.3% (259/2788) | 10.4% (354/3400) | 0.146 | 2.6% (72/2788) | 0.4% (14/3400) | < 0.001 |
| Total (excl. MTP 1–4) | 5.3% (114/2132) | 2.1% (55/2600) | < 0.001 | 2.7% (58/2132) | 0.5% (12/2600) | < 0.001 |
| Tendons  | 2.2% (11/492) | 0.5% (3/600) | 0.014 | 1.2% (6/492) | 0% (0/600) | 0.008 |

MCP, Metacarpophalangeal joint; MTP, metatarsophalangeal joint; PIP, proximal interphalangeal joint of the finger. Significant p-values are shown in bold.

PD signals (PD ≥ 1) were most commonly seen in wrists, i.e., radiocarpal, intercarpal and/or radioulnar joints (7.9% of patient joints vs 2.0% of control joints, p < 0.001), and were infrequent in other locations (≤ 3%; Table 2). A detectable PD signal (PD ≥ 1) at any location occurred in 37/82 (45%) of the patients, as compared to 5/100 (5%) of the controls (p < 0.001).

Tenosynovitis at baseline was found in 10/82 patients (ECU in 3 patients, TPT in 5, CFDL in 1, and both ECU and TPT in 1) and in 3/100 controls (ECU in 2, and CFDL in 1) (p = 0.021).

Ultrasound detected erosions in 13 patients (10 patients had 1, while 3 patients had 2 erosions), whereas none of the controls had any erosions (p < 0.001, Table 3). Of the 16 erosions, 1 was localized in a PIP 2
joint radially, 4 in MCP 2 joints radially, 1 in MCP 5 joints ulnar, 4 in the head of ulna, 2 in MTP 1 medially and 4 in MTP 5 joints laterally. At baseline, 6 of the 16 erosive joints (38%) had synovitis according to ultrasound \((SH \geq 2 \text{ and/or } PD \geq 1)\). Conventional radiographs from baseline detected 1 out of the 16 (6%) erosive abnormalities detected by ultrasound.

Table 3
Baseline ultrasound findings in patients without clinical arthritis at baseline compared to controls.

|                  | Patients (N = 82) | Controls (N = 100) | p-value |
|------------------|-------------------|--------------------|---------|
| **Hands**        |                   |                    |         |
| SH               | 4.0 (4.7)         | 2.1 (2.5)          | 0.001   |
| PD               | 1.0 (1.8)         | 0.04 (0.2)         | <0.001  |
| **MTP1-4**       |                   |                    |         |
| SH               | 4.1 (4.1)         | 7.7 (4.3)          | <0.001  |
| PD               | 0.2 (0.7)         | 0.04 (0.3)         | 0.016   |
| **MTP5**         |                   |                    |         |
| SH               | 0.3 (0.8)         | 0.2 (0.6)          | 0.462   |
| PD               | 0.04 (0.8)        | 0                  | 0.182   |
| **Total (Hands + MTP1-5)** |     |                    |         |
| SH               | 8.4 (7.2)         | 9.9 (5.6)          | 0.102   |
| PD               | 1.3 (2.0)         | 0.1 (0.4)          | <0.001  |
| **Total (Hands + MTP1-5)** |     |                    |         |
| SH               | 8.4 (7.2)         | 9.9 (5.6)          | 0.102   |
| PD               | 1.3 (2.0)         | 0.1 (0.4)          | <0.001  |
| **Tendons**      |                   |                    |         |
| SH               | 0.5 (1.1)         | 0.1 (0.4)          | 0.005   |
| PD               | 0.1 (0.6)         | 0 (0)              | 0.063   |
| ≥ 1 erosion present | 13/82 (16%)   | 0 (0%)             | <0.001  |

Values shown are mean (standard deviation) sum scores unless otherwise indicated. Hands include wrists, metacarpophalangeal joints 1–5, and proximal interphalangeal joints 2–5. SH, Synovial hypertrophy; MTP, metatarsophalangeal joint; PD, power Doppler. Significant p-values are shown in bold.

Table 3 summarizes the ultrasound findings at the patient level. The PD sum scores were higher in patients than in controls. SH showed site-specific differences: in the hands, the SH sum scores were higher among the patients, whereas the SH sum scores in MTP 1–4 were higher among the controls. When excluding the feet, ultrasound-detected synovitis (defined as either \(SH \geq 2\) and/or \(PD \geq 1\)) was noted in 55 patients (67%) and 33 controls (33%) \((p < 0.001)\).

### Ultrasound findings and subsequent arthritis development

Ultrasound arthritis occurred in 55 patients (67%) when excluding the feet, and in 66 patients (81%) when including the feet. Neither the presence of ultrasound synovitis nor the SH or PD sum scores were significantly associated with the development of clinical arthritis (Table 4). However, 10 out of the 13 patients (77%) with \(\geq 1\) baseline erosion on ultrasound developed clinical arthritis during the follow-up period, as compared to 29/69 (42%) of those without erosions \((p = 0.032)\). In the univariable Cox regression analysis, baseline erosions were associated with clinical arthritis development [Hazard Ratio
(HR) 2.8, 95% CI 1.4–5.8, p = 0.005] (Table 4). After including potential confounders (sex, age, symptom duration, smoking habits, ESR, CRP levels, RF status, and ACPA levels) in the Cox regression model, the association between ultrasound-detected erosions and arthritis development remained statistically significant (HR 3.9, 95% CI 1.6–9.4, p = 0.003) (Fig. 2). The PPV for the development of arthritis in patients with baseline erosions was 77% and the NPV was 58%.

### Table 4
Univariable Cox regression analysis of ultrasound sum scores, with development of clinical arthritis as outcome.

| Ultrasound finding Score | N = 82 | Hazard ratio | 95% CI    | p-value |
|--------------------------|--------|--------------|-----------|---------|
| Synovial hypertrophy     |        |              |           |         |
| 0–1                      | 28     | Reference    | 0.65–3.60 | 0.33    |
| 2–3                      | 18     | 1.53         | 0.70–3.13 | 0.31    |
| ≥ 4                      | 36     | 1.48         |           |         |
| Power Doppler            |        |              |           |         |
| 0                        | 45     | Reference    | 0.89–3.15 | 0.11    |
| ≥ 1                      | 37     | 1.68         |           |         |
| Ultrasound arthritis     |        |              |           |         |
| No                       | 27     | Reference    | 0.83–3.50 | 0.15    |
| Yes                      | 55     | 1.70         |           |         |
| Ultrasound tenosynovitis |        |              |           |         |
| No                       | 72     | Reference    | 1.09–5.66 | 0.031   |
| Yes                      | 10     | 2.48         |           |         |
| Erosions                 |        |              |           |         |
| 0                        | 69     | Reference    | 1.37–5.82 | 0.005   |
| ≥ 1                      | 13     | 2.82         |           |         |

SH, Synovial hypertrophy; PD, power Doppler. Ultrasound arthritis and ultrasound tenosynovitis are defined as SH ≥ 2 and/or PD ≥ 1. Significant p-values are shown in bold.

Seven patients started treatment with DMARDs or oral corticosteroids during the follow-up despite no confirmed arthritis upon clinical examination. When we performed a multivariable Cox regression analyses while excluding these patients, erosions remained significantly associated with arthritis development (HR 4.2; 95% CI 1.7–10.0, p = 0.001), while SH and PD were still not significantly associated with arthritis development. In another sensitivity analysis, we restricted the analysis to the initial 3 years when the ultrasound results were completely blinded. During this period, 32/82 patients (39%) developed clinical arthritis, and the association with baseline ultrasound-detected erosions remained significant in the multivariable analysis (HR 3.5, 95% CI 1.3–9.0, p = 0.011).

The presence of baseline tenosynovitis in patients was associated with the development of clinical arthritis in the univariable analysis (Table 4). However, it did not remain statistically significant in the multivariable analysis (HR 1.93, 95% CI 0.75–4.97, p = 0.18)
Discussion

This prospective observational study identifies ultrasound-detected bone erosions as an independent prognostic factor for clinical arthritis development in ACPA-positive at-risk patients without signs of clinical arthritis at baseline. This association persisted when other known predictors were considered, suggesting that ultrasound scanning for erosions is a valuable tool to risk-stratify ACPA-positive patients with MSK pain, at least concerning the outcome of clinical arthritis. Whether or not ultrasound erosions also predict progression of structural joint damage should be addressed in future studies.

Gray-scale ultrasonography findings of SH were not significantly associated with progression to clinical arthritis in the current study, and the existing literature concerning the prognostic value of SH is divergent. Van der Stadt et al did not find a predictive value for GS at the patient level (12), while two studies have reported significant associations with arthritis development, albeit only after excluding the feet (14, 25). A recent Dutch study has shown a predictive value for SH in combination with PD, although SH was not reported separately (22). From the healthy controls included in the current study, we conclude that SH (and thereby ‘ultrasound synovitis’ according to the prevailing definition) is a common finding, also when looking outside the feet (26). Therefore, SH and ultrasound outcomes that include this feature should be interpreted with great caution.

While over-represented among the patients, the PD findings also failed to show a significant prognostic value. As for SH, the literature regarding PD includes both studies that demonstrate significant associations with arthritis development (22) and those that do not (12, 14), although all report numerically increased risk estimates. Differences in ultrasound equipment may influence PD performance across studies, and more recently introduced devices may have superior PD sensitivity than the device used in our study. Nevertheless, we conclude that PD is more specific than SH when comparing ACPA-positive MSK patients to similarly aged controls without MSK pain, but larger studies are warranted to characterize more precisely the possible prognostic value of PD signals in at-risk patients.

Data on tenosynovitis in at-risk patients are scarce. We found an increased prevalence among ACPA-positive patients, and a significant association with progression to clinical arthritis. However, the multivariable analysis did not confirm an independent prognostic value.

Ultrasound erosions were very specific findings in our study, being detected in 16% of the ACPA-positive patients with MSK but not in any of the controls. Since bone-specific effects of ACPA have been discussed extensively in recent years (27, 28), it is intriguing that the ultrasound feature with the strongest prognostic value in our ACPA-positive study population reflects bone damage rather than inflammation. Fewer than half of the joints with ultrasound-detected erosions concurrently had ultrasound-detected synovitis (and none had clinical arthritis), which is compatible with the hypothesis of structural damage preceding arthritis in at least a subset of ACPA-positive individuals (29). The one previous study on ultrasound erosions in ACPA-positive at-risk patients found a HR very similar to ours (14). Taken together, the studies strongly support the use of ultrasound scanning for erosions in ACPA-positive patients with MSK symptoms to improve prognostic capability. Given the general benefit of early initiation of anti-
rheumatic therapy in patients with RA, the issue as to whether patients with ultrasound erosions would benefit from very early pharmacotherapy needs to be addressed in future studies.

A strength of the current study is the long follow-up period, which increases the chances to identify those at risk of developing arthritis after several years. In addition, the large control population places the ultrasound data in perspective, for instance by demonstrating that SH in MTP 1–4 must be interpreted with caution. Furthermore, the ultrasound results were blinded to the patients and the treating physicians, thereby removing the risk of influencing clinical judgement and treatment decisions.

A limitation of the study is that treatment was not defined in the study protocol. Importantly, however, the analyses that excluded the seven patients who were subjected to corticosteroid and/or DMARD therapy without a confirmed clinical arthritis did not alter the results in any substantial way. Another potential limitation is the fact that the ultrasound investigator was not blinded to participant status (patient vs. control). We believe, however, that the risk of over-estimating the findings in patients is limited given the increased SH scores in the control MTPs. Finally, due to practical reasons, arthritis development was not confirmed by a second investigator or compared with ultrasound findings in the same joint. However, the clinical investigators were experienced, and patients were seen by the same doctor at most of the visits.

**Conclusions**

We conclude that bone erosions detected by ultrasound are independent predictors for the development of clinical arthritis in ACPA-positive patients with MSK pain and without baseline arthritis. Thus, ultrasound examinations in this clinical setting should include assessments of erosive abnormalities, in order to improve risk stratification.

**Abbreviations**

ACPA
Anti-citrullinated protein antibodies
ACR
American College of Rheumatology
AU
Arbitrary units
CCP
Cyclic citrullinated Peptides
CFDL
Common flexor digitorum longus
CRP
C-reactive protein
ECU
Extensor carpi ulnaris
ESR  
Erythrocyte sedimentation rate  
DAS28  
Disease Activity Score  
DMARD  
Disease modifying anti-rheumatic drug  
GS  
Grey scale  
HAQ  
Health assessment questionnaire  
IP  
Interphalangeal  
IQR  
Interquartile range  
MCP  
Metacarpophalangeal  
MRI  
Magnetic resonance imaging  
MSK  
Muskoloskeletal  
MTP  
Metatarsophalangeal  
NPV  
Negative predictive value  
PD  
Power Doppler  
PIP  
Proximal interphalangeal  
PPV  
Positive predictive value  
RA  
Rheumatoid arthritis  
RF  
Rheumatoid factor  
SH  
Synovial hypertrophy  
TIRx  
Swedish acronym for “X-tra early rheumatology follow-up”  
TPT  
Tibialis posterior tendon
Declarations

Ethics approval and consent to participate

The study was conducted in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Regional Ethics Committee in Linköping, Sweden (DnR 220-09 and 2015/236-32), and all participants gave written informed consent to participate.

Consent for publication

Not applicable

Acknowledgments

We thank the TIRx patients and control subjects for their participation in this study.

Authors’ contributions

MZ, TS, and AK conceived the study. MZ performed the ultrasound examinations and was responsible for study coordination. EE, JC, ÅR, TS and AK were involved in the recruitment and characterization of patients. HBH and MZ developed the ultrasound protocols. MM and MZ performed statistical analyses. KM was responsible for the laboratory analyses. MZ, MM, and AK drafted the manuscript and received critical input from all the co-authors.

Funding

This work was supported by the Swedish Society of Medicine [grant number, SLS-682741], King Gustaf V’s 80-year foundation [FAI-2017-0420], the Swedish Rheumatism Association [R-754141], and the Östergötland County Council [LIO-700501].

Competing interests: MZ reports personal fees from AbbVie, Celgene, Pfizer and Novartis. JC reports personal fees from Eli Lilly, Novartis and UCB. AK reports personal fees from Pfizer, BMS, UCB, and Roche, and previous employment at Sanofi Genzyme. HBH has received honorariums as a speaker from AbbVie, Bristol-Myers Squibb, Roche, UCB Pharma, Novartis and Pfizer. All fees <10,000 USD each.

Availability of data and materials

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

References

1. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid
2. Verheul MK, Bohringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW, et al. Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals. Arthritis Rheumatol. 2018;70(11):1721–31.

3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.

4. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. rd, et al.

5. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.

6. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65(7):845–51.

7. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2958–67.

8. Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D'Agostino MA, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol. 2005;32(12):2485–7.

9. Porta F, Radunovic G, Vlad V, Micu MC, Nestorova R, Petranova T, et al. The role of Doppler ultrasound in rheumatic diseases. Rheumatology. 2012;51(6):976–82.

10. Backhaus M, Burmester GR, Sandrock D, Loreck D, Hess D, Scholz A, et al. Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints. Ann Rheum Dis. 2002;61(10):895–904.

11. Freeston JE, Wakefield RJ, Conaghan PG, Hensor EM, Stewart SP, Emery P. A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools. Ann Rheum Dis. 2010;69(2):417–9.

12. van de Stadt LA, Bos WH, Meursinge Reynolds M, Weringa H, Turkstra F, van der Laken CJ, et al. The value of ultrasonography in predicting arthritis in auto-antibody positive arthralgia patients: a prospective cohort study. Arthritis Res Ther. 2010;12(3):R98.

13. van den Berg R, Ohndorf S, Kortekaas MC, van der Helm-van Mil AHM. What is the value of musculoskeletal ultrasound in patients presenting with arthralgia to predict inflammatory arthritis development? A systematic literature review. Arthritis Res Ther. 2018;20(1):228.
14. Nam JL, Hensor EM, Hunt L, Conaghan PG, Wakefield RJ, Emery P. Ultrasound findings predict progression to inflammatory arthritis in anti-CCP antibody-positive patients without clinical synovitis. Ann Rheum Dis. 2016;75(12):2060–7.

15. Pratt AG, Lorenzi AR, Wilson G, Platt PN, Isaacs JD. Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required? Arthritis Res Ther. 2013;15(5):R118.

16. Witt M, Mueller F, Nigg A, Reindl C, Leipe J, Proft F, et al. Relevance of grade 1 gray-scale ultrasound findings in wrists and small joints to the assessment of subclinical synovitis in rheumatoid arthritis. Arthritis Rheum. 2013;65(7):1694–701.

17. Camerer M, Ehrenstein B, Hoffstetter P, Fleck M, Hartung W. High-resolution ultrasound of the midfoot: sonography is more sensitive than conventional radiography in detection of osteophytes and erosions in inflammatory and non-inflammatory joint disease. Clin Rheumatol. 2017;36(9):2145–9.

18. Wakefield RJ, Gibbon WW, Conaghan PG, O'Connor P, McGonagle D, Pease C, et al. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum. 2000;43(12):2762–70.

19. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–8.

20. Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS, Ostergaard M. Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum. 2003;48(4):955–62.

21. Horton SC, Tan AL, Wakefield RJ, Freeston JE, Buch MH, Emery P. Ultrasound-detectable grey scale synovitis predicts future fulfilment of the 2010 ACR/EULAR RA classification criteria in patients with new-onset undifferentiated arthritis. RMD Open. 2017;3(1):e000394.

22. van der Ven M, van der Veer-Meerkerk M, Ten Cate DF, Rasappu N, Kok MR, Csakvari D, et al. Absence of ultrasound inflammation in patients presenting with arthralgia rules out the development of arthritis. Arthritis Res Ther. 2017;19(1):202.

23. Terslev L, Naredo E, Aegerter P, Wakefield RJ, Backhaus M, Balint P, et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 2: reliability and application to multiple joints of a standardised consensus-based scoring system. RMD Open. 2017;3(1):e000427.

24. Hammer HB, Kvien TK. Ultrasonography shows significant improvement in wrist and ankle tenosynovitis in rheumatoid arthritis patients treated with adalimumab. Scand J Rheumatol. 2011;40(3):178–82.

25. van Beers-Tas MH, Blanken AB, Nielen MMJ, Turkstra F, van der Laken CJ, Meursinge Reynders M, et al. The value of joint ultrasonography in predicting arthritis in seropositive patients with arthralgia: a prospective cohort study. Arthritis Res Ther. 2018;20(1):279.
26. Padovano I, Costantino F, Breban M, D'Agostino MA. Prevalence of ultrasound synovial inflammatory findings in healthy subjects. Ann Rheum Dis. 2016;75(10):1819–23.

27. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Investig. 2012;122(5):1791–802.

28. Harre U, Lang SC, Pfeifle R, Rombouts Y, Fruhbeisser S, Amara K, et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun. 2015;6:6651.

29. Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. 2014;73(5):854–60.

**Figures**

**Figure 1**

Distribution of patients during the study.
Figure 2

Clinical arthritis development in relation to baseline ultrasound erosions. Survival plot illustrating the development of clinical arthritis during follow up in relation to the presence of ultrasound erosions at baseline among patients who had anti-citrullinated protein antibodies and musculoskeletal pain.